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Toxicogenomics can have a significant
impact on our ability to predict toxic haz-
ards by the identiﬁcation of mechanistically
relevant markers of toxicity. Indeed, several
recent studies have shown the potential of
DNA microarray technology to reveal
chemical and mechanism-speciﬁc signatures
from in vivo and in vitro models treated
with well-characterized toxins (Bartosiewicz
et al. 2001a, 2001b; Bulera et al. 2001;
Burczynski et al. 2000; Fielden and
Zacharewski 2001; Hamedeh et al. 2002a,
2002b; Harries et al. 2001; Nuwaysir et al.
1999; Thomas et al. 2001; Waring et al.
2001a, 2001b). However, before the full
potential of toxicogenomics can be realized,
a number of important questions regarding
the robustness and reproducibility of the
data generated must be addressed. 
To identify and address some of the
issues, challenges, and opportunities afforded
by the emerging ﬁeld of toxicogenomics, the
Health and Environmental Sciences Institute
(HESI) of the International Life Sciences
Institute (ILSI; http://www.ILSI.org) formed
a committee to develop a collaborative scien-
tiﬁc program to address these areas (Pennie
et al. 2004). Experts and advisers from acad-
emia and government laboratories partici-
pated on the committee, together with
approximately 30 companies from the phar-
maceutical, agrochemical, chemical, and
consumer product industries. The commit-
tee was divided into several working groups
conducting large-scale cross-laboratory stud-
ies in the ﬁelds of hepatotoxicity, nephrotox-
icity, and genotoxicity. In addition, a fourth
working group was established to address the
issue of database development. The goal of
the Hepatotoxicity Working Group
(HWG), outlined by Ulrich et al. (2004) in
this issue, was to evaluate and compare bio-
logical and gene expression responses in rats
exposed to two well-studied hepatotoxins
(cloﬁbrate and methapyrilene), using a stan-
dard experimental protocol, and to address
the following issues: a) how comparable are
the biological and gene expression data from
different laboratories running identical
in vivo studies; b) how reproducible are the
data generated across laboratories using the
same microarray platform; c) how do data
compare using different microarray plat-
forms; d) how do data compare using RNA
from pooled and individual animals; e) do
the gene expression changes demonstrate
time- and dose-dependent responses that
correlate with known biological markers
of toxicity? 
As part of the experimental program of
the HWG, the biological response in rats to
the model hepatotoxin cloﬁbrate was inves-
tigated. Clofibrate, a hypolipidemic drug,
was chosen as a test material for this study
because of its well-characterized hepatotoxic
effects in rodents. Cloﬁbrate was developed
and marketed in the 1960s for the treat-
ment of high cholesterol and triglycerides in
humans (IARC 1996; Tucker and Orton
1993) and is still used in the treatment of
hypercholesterolemia. However, adminis-
tration to rodents results in a characteristic
increase in liver weight. This liver weight
increase is due to hepatocyte hyperplasia
and hypertrophy associated with distinctive
morphological and biochemical effects
(Tosh et al. 1989). The biochemical effects
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Microarrays have the potential to signiﬁcantly impact our ability to identify toxic hazards by the
identification of mechanistically relevant markers of toxicity. To be useful for risk assessment,
however, microarray data must be challenged to determine reliability and interlaboratory repro-
ducibility. As part of a series of studies conducted by the International Life Sciences Institute
Health and Environmental Science Institute Technical Committee on the Application of
Genomics to Mechanism-Based Risk Assessment, the biological response in rats to the hepatotoxin
clofibrate was investigated. Animals were treated with high (250 mg/kg/day) or low (25
mg/kg/day) doses for 1, 3, or 7 days in two laboratories. Clinical chemistry parameters were meas-
ured, livers removed for histopathological assessment, and gene expression analysis was conducted
using cDNA arrays. Expression changes in genes involved in fatty acid metabolism (e.g., acyl-CoA
oxidase), cell proliferation (e.g., topoisomerase II-α), and fatty acid oxidation (e.g., cytochrome
P450 4A1), consistent with the mechanism of cloﬁbrate hepatotoxicity, were detected. Observed
differences in gene expression levels correlated with the level of biological response induced in the
two in vivo studies. Generally, there was a high level of concordance between the gene expression
proﬁles generated from pooled and individual RNA samples. Quantitative real-time polymerase
chain reaction was used to conﬁrm modulations for a number of peroxisome proliferator marker
genes. Though the results indicate some variability in the quantitative nature of the microarray
data, this appears due largely to differences in experimental and data analysis procedures used
within each laboratory. In summary, this study demonstrates the potential for gene expression pro-
ﬁling to identify toxic hazards by the identiﬁcation of mechanistically relevant markers of toxicity.
Key words: cDNA array, cloﬁbrate, cross-laboratory studies, gene expression proﬁling, liver, mem-
brane array, microarray, peroxisome proliferator, rat. Environ Health Perspect 112:428–438
(2004). doi:10.1289/txg.6677 available via http://dx.doi.org/ [Online 15 January 2004]of clofibrate are triggered through binding
of the chemical to the peroxisome prolifera-
tor–activated receptor-alpha (PPARα),
causing a pleiotropic response involving the
induction of a number of proteins involved
in fatty acid β-oxidation (Lapinskas and
Corton 1999; Lindquist et al. 1998, for
example). Cloﬁbrate administered at a dose
of 250 mg/kg/day to rats causes hepatic
parenchymal cells to increase in size
(Karbowski et al. 1999), induces peroxi-
somes, and produces liver tumors in
20–91% of chronically treated rats (Ashby
et al. 1994; Doull et al. 1999; Hartig et al.
1982; Reddy and Qureshi 1979; Svoboda
and Azarnoff 1979). This dose also
decreases both basophilic material in the
cytoplasm and vacuolation within 1 week,
with maximal effects being observed at
2 weeks. For the purpose of the current
study, 250 mg/kg/day was chosen as the high
dose to induce peroxisome proliferation. The
lower dose of 25 mg/kg/day was selected as
one-tenth of the conﬁrmed toxic dose.
To help address the goals of the HWG,
the aims of this study were a) to investigate
whether the gene expression profiles
observed after exposure to cloﬁbrate corre-
lated with changes in known biological
markers of hepatotoxicity (as identified by
histopathology and clinical chemistry para-
meters), and b) to assess the reproducibility
of the gene expression changes across dif-
ferent laboratories on a single microarray
platform using RNA from identical in vivo
studies conducted separately at different
locations. In addition, comparison of gene
expression data generated using RNA from
pooled and individual animals was con-
ducted, together with conﬁrmatory analysis
of a subset of genes using quantitative real-
time polymerase chain reaction (PCR).
Materials and Methods
Different components of the study were con-
ducted in individual laboratories. Table 1
shows the involvement of each laboratory.
Chemicals 
Cloﬁbrate [2-(p-chlorophenoxy)-2-methyl-
propionic acid ethyl ester] (CAS no. 637-
07-0) was obtained from Sigma Chemical
Corporation (St. Louis, MO, USA) and
stored according to manufacturer instruc-
tions. The same batch was used by both
laboratories performing the in vivo studies
and had a purity of 99.7%. 
Animals and Treatment 
In vivo studies were conducted at Abbott
Laboratories (Abbott Park, IL, USA) and
GlaxoSmithKline (GSK) (Ware, U.K.), as
shown in Table 1. The male Sprague-
Dawley rat was chosen as the test species, as
this sex, strain, and species has previously
been used to demonstrate the hepatotoxic
effect of clofibrate (e.g., Aberg and
Appelkvist 1994; Lake et al. 1984a, 1984b;
Lundgren and DePierre 1989) and is cur-
rently used by laboratories in the consor-
tium. The animals [Crl:CD(SD)BR, also
referred to as Crl:CD(SD)IGS VAF+], were
obtained from Charles River Laboratories,
Inc. (Margate, Kent, U.K.) for the GSK
study and Charles River Laboratories, Inc.
(Wilmington, MA, USA) for the Abbott
study. Rats were 57 days of age (Abbott) or
60–66 days of age (GSK) and weighed
233.4–274.0 g (Abbott) or 258.0–316.0 g
(GSK) at the start of treatment. Upon
arrival, all rats were acclimatized for 6 days
prior to beginning treatment and were ran-
domly assigned to the treatment groups
listed in Table 2. Rats were housed in
groups of 4 or 2 of the same sex and treat-
ment group in plastic solid-bottomed cages
with Beekay bedding (B&K Universal Ltd,
Hull, U.K.) (GSK) or suspended wire cages
(Abbott). Rats were dosed once daily via
gavage for a period of up to 7 days. The
dose volume was 10 mL/kg. Doses for each
rat were calculated based upon body weight
data on the day of dosing. Food (see Table 3
for details of diet for each in vivo study) and
water were available ad libitum. Rats were
fasted overnight after their last treatment,
euthanized the following morning under
halothane/isoﬂurane anesthesia, and submit-
ted for necropsy. Data collected as part of
the in vivo studies included clinical chem-
istry, organ weights, and macroscopic and
microscopic pathology.
Hematology and Clinical Chemistry 
Blood samples (approximately 5 mL/rat)
were collected via the abdominal vein at
necropsy. A range of hematology and clinical
chemistry parameters were measured
(Table 4). For the study conducted at Abbott
Laboratories, serum from animals was
analyzed on an Abbott Aero set (Abbott
Diagnostics, Abbott Park, IL, USA) accord-
ing to manufacturer instructions. For the
study conducted at GSK (U.K.), plasma
from animals was analyzed on an Advia 1650
(Bayer Diagnostics, Tarrytown, NY, USA).
Histology
A portion of the left lateral lobe was taken
for histopathology in all studies (stored in
10% buffered saline). The right lobe
(50–100 mg) was taken for measurement of
acyl-CoA oxidase (ACOX) activity, and the
remaining tissue was ﬂash frozen for RNA
isolation. Tissues to be examined histologi-
cally were fixed in 10% neutral-buffered
formalin and subsequently sectioned and
stained with hematoxylin and eosin.
Acyl-CoA Oxidase Enzyme Assay
At necropsy, samples of liver (50–100 mg)
were collected from all treatment groups for
triplicate measurement of ACOX activity.
Liver was collected, flash-frozen in liquid
nitrogen, and stored at –80°C. Analysis of
ACOX activity was performed at Abbott
Laboratories using spectrophotometric
analysis via a modiﬁcation of the method of
Small et al. (1985). Brieﬂy, pieces of frozen
tissue were placed in 1 mL of 10% (w/v)
sucrose, 3 mM imidazole, pH 7.4, and
immediately homogenized by sonication on
ice. The resulting homogenate was cen-
trifuged at 7,000 × g for 10 min and lipid, if
present, was aspirated. A portion of the
supernatant was used in the Bradford assay
(Bradford 1976) to assess protein concentra-
tion. Supernatant (10 µL) in quadruplicate,
containing 10–15 mg/mL protein, was
added to a 96-well plate. Two hundred
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Table 1. Laboratories involved in the study.a
Company and location Study
Abbott Laboratories, Chicago, Illinois, USA In vivo exposures, clinical chemistry, and histopathology
GSK, Ware, Hertfordshire, U.K. In vivo exposures, clinical chemistry, and histopathology
GSK, Research Triangle Park, North Carolina, USA Gene expression analysis of pooled samples from 
days 1, 3, and 7
Unilever Research Sharnbrook, Bedfordshire, U.K. Gene expression analysis of pooled samples from
days 1, 3, and 7
U.S. EPA, Research Triangle Park, North Carolina, USA Gene expression analysis of individual samples from day 7
Table 2. Study design.a
Cloﬁbrate Cloﬁbrate
Test dosage concentration  Duration of treatment
Group material (mg/kg/day) (mg/mL) 1 day 3 days 7 days
T0 Vehicleb 00 4 c 4c 4c
T1 Cloﬁbrate 25 2.5 4 4 4
T2 Cloﬁbrate 250 25 4 4 4
aSatellite rats were also assigned to groups for toxicokinetic measurements. b0.2% hydroxypropyl methyl cellulose in
sterile water. cNumber of male rats. eighty microliters of the reaction mixture
(40 mM aminotriazole, pH 7.4; 11 mM
potassium phosphate, monobasic; 0.2%
Triton X-100; 0.08 mg horseradish peroxi-
dase type IV-A; 0.05 mM 2,7-dichlorodihy-
drofluorescein diacetate) was then added
and the mixture preincubated in the dark
with mixing for 2 min. The reaction was
started by the addition of 10 µL of 3 mM
palmitoyl-CoA, lithium salt, and the rate of
dye oxidation was determined at 30°C, λ =
502 nm for 3 min using a Spectramax plate
reader (Molecular Devices, Sunnydale, CA,
USA). Rates were corrected for substrate
blank. The rate of oxidation was the net of
substrate initiated minus nonsubstrate oxi-
dation. Rates were normalized for protein
concentration and expressed as millimolar
per minute per milligram using a 2,7-
dichlorodihydroﬂuorescein extinction coefﬁ-
cient of 9,100 M–1cm–1 or as fold increase
relative to control values. 
RNA Isolation and Distribution
At necropsy, liver tissue was quickly
chopped into small pieces and ﬂash-frozen
in liquid nitrogen. RNA isolation was per-
formed at Abbott using Trizol reagent
(Invitrogen Life Technologies, Carlsbad,
CA, USA) according to manufacturer proto-
col, and at GSK (U.K.) using RNeasy kits
(Qiagen, Crawley, West Sussex, U.K.)
according to manufacturer instructions. A
portion of the RNA from the four animals
in each treatment group was pooled, using
equivalent amounts. The remainder was
retained as individual samples. RNA sam-
ples were aliquoted and precipitated in
ethanol and ammonium acetate for ship-
ment to the microarray analysis laboratories. 
cDNA Gene Expression Arrays
cDNA probes were prepared according to
manufacturer instructions and hybridized
to Atlas Rat Toxicology II arrays (Clontech,
Palo Alto, CA, USA) containing 465 genes.
Pooled RNA samples were analyzed by
GSK (U.S.) and Unilever Research (ULR;
Sharnbrook, Bedfordshire, U.K.) using trip-
licate arrays. The U.S. Environmental
Protection Agency (U.S. EPA) analyzed
RNA samples from individual animals (n =
4/group). Other differences in interlabora-
tory experimental protocols are noted in
Table 3.
Image Capture and Analysis
Probed arrays were developed using
phosphorimagers [GSK (U.S.): Cyclone
(Packard Bioscience Company, Meriden,
CT, USA); U.S. EPA: FX (BioRad, Hercules,
CA, USA)] or exposed to X-ray ﬁlm for up
to 5 days at –70°C (ULR). After scanning,
individual image files were analyzed using
the AtlasImage 2.0 program (Clontech), and
the intensity of each spot was determined.
The complete data set is currently being
submitted to ArrayExpress (EMBL-European
Bioinformatics Institute, Hinxton, U.K.;
http://www.ebi.ac.uk/arrayexpress) and will
be available for public download by the sec-
ond quarter of 2004. Accession numbers
referencing this data set will be available on
the HESI web site (http://hesi.ilsi.org/
index.cfm?pubentityid=120).
Data Analysis
U.S. Environmental Protection Agency.
Background was subtracted from intensity
values and log2 values were calculated for
use in the analysis. For intensity values less
than background, 0 was used in the analy-
sis. Values less than twice background were
flagged as not expressed. Genes that were
not expressed in at least three of four arrays
for at least one of three treatment groups
were removed from further analysis.
Normalization was carried out using a one-
way analysis of variance (ANOVA) [model
log(intensity) = array], so each array was
centered around 0. Each gene was then
analyzed in a one-way ANOVA [log(inten-
sity) = treatment], and where the overall F
test was signiﬁcant, indicating some differ-
ences among treatment groups, the low-
and high-dose groups were each tested for
any difference from control using a t test. A
significant change was deemed to have
occurred where p < 0.05.
GlaxoSmithKline. Normalization and
statistical analysis were by normalized local
regression (Kepler et al. 2002). Fold change
counts were accepted if the intensity of the
signal was considered adequate by mean log
intensity and by visual inspection of adjusted
intensities and if p-values reﬂected consistent
adjusted intensities greater than 10 pixels. 
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Table 4. Hematology and clinical chemistry
measurements.
Hematology Clinical chemistry
Hemoglobin Alkaline phosphatase
Hematocrit Alanine aminotransferase
Red blood cell count Aspartate aminotransferase
Reticulocyte count Triglycerides
Erythrocytic indices Globulin
White blood cell count Glucose
Differential white blood  Urea (nitrogen)
cell count
Platelet count Total protein
Prothrombin time Albumin
Activated partial  Creatinine
thromboplastin time
Fibrinogen Cholesterol
Sodium
Potassium
Calcium
Total bilirubin
Chloride
Phosphorus
Glutamate dehydrogenase
Sorbitol dehydrogenase
Gamma glutamyltransferase
Table 3. Experimental procedures used in each laboratory performing the microarray analysis.
Method U.S. EPA GSK ULR
Laboratory supplying RNA  Abbott (U.S.) GSK (U.K.) GSK (U.K.)
Source of animals Charles River  Charles River Charles River
Laboratories Inc.,  Laboratories Inc,  Laboratories Inc, 
(U.S.) (U.K.) (U.K.)
Sex/strain/species Male Sprague-  Male Sprague-  Male Sprague- 
Dawley rat Dawley rat Dawley rat
Diet LabDiet certiﬁed  Rat and mouse no.1 Rat and mouse no.1
Rodent diet 5002  expanded (SDS, U.K.) expanded 
pellets (LabDiet, U.S.)  (SDS, U.K.)
RNA isolation method Trizol  RNeasy kit RNeasy kit
(Invitrogen) (Qiagen) (Qiagen)
Isotope for probe labeling 32P 33P 33P
Membrane condition New for each  New for each  Stripped and 
sample sample reprobed (according
to manufacturer’s
instructions)
Hybridization temperature 68°C 62°C 68°C
Hybridization time 15–18 hr 16 hr 16 hr
Image development time Up to 96 hr 72 hr Up to 120 hr
Image capture medium Phosphorimaging plate Phosphorimaging plate X-ray ﬁlm
Image capture device FX Cyclone Image Master
(BioRad) (Packard Bioscience Co.) (Amersham
Biosciences,
Cardiff, U.K.)
Image capture software Quantity 1 OptiQuant Liscap
(BioRad) (Packard Bioscience Co.) (Amersham
Biosciences)
Data extraction AtlasImage 2.0 AtlasImage 2.0 AtlasImage 2.0
(Clontech) (Clontech) (Clontech)
Data analysis ANOVA Linear regression ManualUnilever Research. Background was
subtracted from intensity values and a
global normalization performed using
AtlasImage 2.0 (Clontech). For intensity
values less than background, zero was used
in the analysis, indicating “not expressed.”
All adjusted intensity values were visually
inspected and genes that were not expressed
in at least two of three arrays were removed
from further analysis. 
Quantitative real-time polymerase chain
reaction. Total RNA was isolated from sam-
ples as previously described. Quantitative
real-time PCR was conducted using
TaqMan and SYBR green methods.
Briefly, primers were designed for ACOX,
apolipoprotein A-1 (APO-A1), cate-
cholamine O-methyltransferase (COMT),
cytochrome P450 4A1 (CYP4A1), cytosolic
epoxide hydrolase (CEH), hydroxyacyl-CoA
dehydrogenase (HCD), paraoxonase 1
(PON1), PPARα, and phosphoenolpyru-
vate carboxykinase (PEPCK) with Primer
Express software (PerkinElmer Applied
Biosystems, Foster City, CA, USA) follow-
ing the manufacturer’s advice for optimal
primer design for the TaqMan reactions.
For the SYBR green method, Clontech
sequences were used. Primer and probe
sequences are listed in Table 5. Samples
were diluted to 10 ng/µL prior to analysis
(ABI Prism 7700 Sequence Detection
System; PerkinElmer). Forward and reverse
primers and probes were diluted to the
appropriate concentrations to make the
probe/primer master mix. SYBR green
primers were used at 300 nM ﬁnal concen-
tration, TaqMan primers at 900 nM, and
TaqMan probes at 200 nM. The master mix
was prepared according to manufacturer
protocol (without probes and primers) and
30 µL master mix, 5 µL RNA, and 15 µL
probe/primer mix were aliquoted per well
into the gene plate. The plate was sealed and
centrifuged at 3,000 × g for 10 sec. The
reaction was incubated at 48°C for 30 min
[reverse transcriptase (RT) step], denatured
at 95°C for 10 min (Amplitaq activation
and RT denaturation), then subjected to
40 PCR cycles of 94°C for 15 sec and 60°C
for 1 min. Values of fold change in expres-
sion were graphed for comparison purposes. 
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Table 5. Primer pairs and probes used for quantitative real-time PCR. 
GenBank
Gene accession  no.a Forward primer Probe Reverse primer
TaqMan primers and probes
CEH X65083 ATGAGCCCCAGTCCCAATG FAM-ACATACACAGTGGCGAAATCCTTCACCCT-TAMRA CCGCTGTCCTTGACTGCAT
ACOX J02752 TGCTGGCATCGAAGAATGTC FAM-GCCCGCCGCAGGCCATT-TAMRA GGAATCCCACTGCTGTGAGAA
CYP4A1 X07259 TCCAGGTTTGCACCAGACTCT FAM-CCCGACACAGCCACTCATTCCT-TAMRA TCCTCGCTCCTCCTGAGAAG
PPARa M88592 TGGAGTCCACGCATGTGAAG FAM-CTGCAAGGGCTTCTTTCGGCGA-TAMRA CGCCAGCTTTAGCCGAATAG
COMT M60753 CAGCAGCTCACACCACATCTC FAM-TCTGAAGAATGAGTCACAAGCTTTCC-TAMRA GGCGTGCACCACCATACC
PON1 U94856 GGTAGCAGATGGATTTGATTTCG FAM-TGGCATTGGCATTTCCCTTGATGG-TAMRA CAGCAATTCAGCGATATAGACATACTT
PEPCK K03248 ACAGGCAAGGTCATCATGCA FAM-ACCCCTTCGCTATGCGGCCC-TAMR TGCCGAAGTTGTAGCCAAAGA
HCD K03249 CCTCTGAAGGAATGGCAAAGC FAM-CAGGGCCCCACGGCAGCA-TAMR CGCAGAAGGCTGAATCACAGT
APO-A1 X00558 GTGTGAGCTGAGCCAACACTTT FAM-TTCCTCATAGAGTCCTGTCAGGTCGGGA-TAMRA TAGATCTGAGGCTCAGGCTTGAT
SYBRgreen primer pairs
CEH X65083 CAGTCCCGTGCAGTCCAAATGATG CATGTCTATAGCTAGAACAC GAAAGCC
ACOX J02752 CTCATCTTCGAGGCTTGGAAACCAC ATTTCACGGATAGGGACAA CAAAGGC
CYP4A1 X07259 CAAAGCCTACTTAATTGTCTATGACCC CATCAGTCGAATGGAGTC AGCCATG
PPARα M88592 CAGGTTACCTTGCTGAAGTACGGTG AAATGTCACTGTCATCCAG TTCGAGG
COMT M60753 AGCCAGTCCACAACCTGATCATGG GTACTCCCGAATCACTGC ATCCATG
PON1 U94856 TGGGCCTGTCATGGTCCAATGTTG TTATCCACAAGGGTGTCAA AGCTGAG
PEPCK K03248 CAAGATTGGTATTGAGCTGACAGACTC AAGCAGTGAGTTCCCACC GTATCC
HCD K03249 AATCGGATGTTGGCTCCCTATTACAAC GTGGCAATGATGGTCCAG TAAGGC
APO-A1 X00558 CAGCTAGGCCCAGTGACTCAGGAG CGCAGCGCGTCTGCATTCACACG
aFrom GenBank (http://www.ncbi.nih.gov/GenBank/). 
Table 6. Summary results from selected clinical chemistry and pathology parameters as determined in the
two in vivo studies.a
Sampling Cloﬁbrate daily dose (mg/kg/day)
Parameters day 0 25 250
Total cholesterol (mmol/L)
GSK (U.K.) 1 2.01 ± 0.40 1.58 ± 0.10* (78.6%) 0.96 ± 0.27* (47.8%)
31 .77 ± 0.26 1.76 ± 0.30 (99.4%) 1.31 ± 0.15* (74.0%)
71 .68 ± 0.15 1.91 ± 0.24 (113.7%) 1.09 ± 0.20* (64.9%)
Abbott  1 1.74 ± 0.55 1.61 ± 0.30 (92.5%) 1.22 ± 0.30 (70.1%)
31 .90 ± 0.19 1.61 ± 0.20* (84.7%) 1.28 ± 0.23 (67.4%)
71 .30 ± 0.31 1.37 ± 0.37 (105.4%) 0.88 ± 0.31 (67.7%)
Triglycerides (mmol/L)
GSK (U.K.) 1 0.89 ± 0.11 0.73 ± 0.06 (82.0%) 0.87 ± 0.21 (97.7%)
30 .94 ± 0.04 1.02 ± 0.39 (108.5%) 0.70 ± 0.15* (74.5%)
71 .03 ± 0.46 0.95 ± 0.09 (92.2%) 0.78 ± 0.11 (75.7%)
Abbott  1 0.58 ± 0.36 0.44 ± 0.26 (75.9%) 0.89 ± 0.45 (153.4%)
30 .58 ± 0.20 0.53 ± 0.20 (91.4%) 0.47 ± 0.05 (81.0%)
70 .27 ± 0.07 0.32 ± 0.09 (118.5%) 0.39 ± 0.12 (144.4%)
Globulins (g/L)
GSK (U.K.) 1 19.98 ± 2.63 19.60 ± 0.65 (98.1%) 18.43 ± 1.37 (92.2%)
3 19.15 ± 1.64 21.25 ± 1.58 (110.0%) 15.98 ± 2.33* (83.3%)
7 18.88 ± 0.71 19.13 ± 0.43 (101.3%) 15.33 ± 1.14* (81.2%)
Abbott  1 13.25 ± 1.26 12.75 ± 1.26 (96.2%) 12.75 ± 0.96 (96.2%)
3 13.25 ± 0.50 12.50 ± 1.73 (94.3%) 11.67 ± 0.58 (88.1%)
7 12.25 ± 0.96 12.50 ± 1.73 (102.0%) 12.00 ± 0.82 (98.0%)
Albumin (g/L)
GSK (U.K.) 1 37.45 ± 1.01 38.55 ± 1.02 (102.9%) 39.25 ± 1.51 (104.8%)
3 38.35 ± 1.95 39.58 ± 1.26 (103.2%) 41.88 ± 1.37* (109.2%)
7 38.78 ± 0.42 40.78 ± 0.54* (105.2%) 43.35 ± 0.82* (111.8%)
Abbott  1 45.75 ± 1.26 43.00 ± 2.16 (94.0%) 46.25 ± 0.98 (101.1%)
3 45.50 ± 1.73 43.50 ± 2.08 (95.6%) 44.67 ± 1.53 (98.2%)
7 43.25 ± 1.50 43.00 ± 1.41 (99.4%) 43.50 ± 0.57 (100.6%)
Mitotic index, hepatocellular
GSK (U.K.) 1 0/4 1/4 3/4
3 0/4 2/4 4/4
7 0/4 1/4 1/4
Abbott 1 0/4 3/4 2/4
3 0/4 3/4 2/4
7 0/4 0/4 0/4
aData shown are the mean (n = 4) ± SD. Numbers in parentheses are percentage of control values. *Statistically signiﬁ-
cant at the 5% level (p < 0.05). Results
Animal Observations, Clinical
Chemistry, and Histopathology 
Two separate in vivo studies were con-
ducted: one at Abbott Laboratories and one
at GSK (U.K.). Differences in the level of
biological response induced in the two
in vivo studies were observed by variance in
the percentage of liver weight increase at
days 3 and 7. For example, the high-dose
(250 mg/kg/day) group at day 3 demon-
strated a 15% increase in liver weight rela-
tive to body weight in the GSK study,
compared with a 3% liver weight increase
in the Abbott study. This relationship was
similarly reflected in the 7-day high-dose
group, where a 31% liver weight increase
was observed in the GSK study, compared
with a 15% increase in the Abbott study.
Observed changes in clinical chemistry
parameters also indicated differences in the
biological response of the in vivo study con-
cordant with the differences in liver weight
increase (Table 6). For example, a signifi-
cant reduction in total cholesterol levels was
seen in the GSK study at the high dose for
all time points. However, the Abbott study
demonstrated a signiﬁcant reduction at only
one dose and time point. Similarly, a reduc-
tion in globulins and triglycerides was more
pronounced in the GSK study, as was the
increase in albumin concentrations. An
increase in hepatocellular mitotic activity
(as indicated by numbers of mitotic ﬁgures
noted in the liver sections) was detected in
both studies in the day 1, and most notably,
day 3 high- and low-dose groups. However,
by day 7, the incidence of mitotic figures
had decreased. An increase in clotting time
after a single dose of clofibrate, associated
with biosynthetic function changes in the
liver after the disturbance of liver function,
was also found. 
Acyl-CoA Oxidase Activity
In both in vivo studies, an increase in
ACOX activity 2–3 times that of the con-
trol was demonstrated at the high-dose
(250 mg/kg/day) level only (Figure 1).
There was no signiﬁcant difference between
ACOX levels in the control and low-dose
(25 mg/kg/day) groups.
Microarray Analysis
Reproducibility of microarray results across
different laboratories. GSK (U.S.) and ULR
analyzed pooled samples from animals
treated with high (250 mg/kg/day) and low
(25 mg/kg/day) doses of cloﬁbrate for 1, 3,
or 7 days at GSK (U.K.). Comparison of the
gene expression data obtained from pooled
RNA samples indicated that genes previously
described as being regulated by cloﬁbrate or
that are associated with the histopathology
findings were detected. In general, a dose-
related response in gene expression was
observed with the low dose, demonstrating
little deviation from control levels of gene
expression. The high-dose tissues demon-
strated typical PPARα-mediated responses
associated with β-oxidation of fats, metabo-
lism of bile acids and steroids, and early cell
proliferation [e.g., HCD, 3-ketoacyl-CoA
thiolase A + B (3KCTA+B), ACOX, alde-
hyde dehydrogenase 1 (ADH1), and
CYP4A1]. Examples of some of these gene
expression changes are shown in Figure 2. It
is apparent that although the changes in gene
expression observed for these ﬁve genes were
demonstrated by both laboratories, there are
quantitative differences in the fold change
values observed between the two sites.
The upregulation of a variety of cell
proliferation–associated genes (e.g., G2/M-
specific cyclin B1, cyclin-dependent
kinase 1, DNA topoisomerase II alpha,
c-myc protooncogene, pololike serine-threo-
nine protein kinase, and cell division con-
trol protein 20) began on or before day 1
and peaked at some point between days 3
and 7. By day 7, cell proliferation genes
were downregulated. The chronology of
this gene expression agrees with the histo-
logic diagnoses of mitotic ﬁgures in the tis-
sue, where an increase in mitotic ﬁgures was
detected in the day 1, and most notably,
day 3 high- and low-dose groups. However,
by day 7, the incidence of mitotic figures
had decreased. The clustering of genes asso-
ciated with the G2/M transition point sug-
gests that in the rat, the polyploid cells
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Figure 1. ACOX activity in rat liver samples from two in vivo studies: (A) Abbott Laboratories and (B) GSK
(U.K.). mpk, mg/kg/day. Rats received clofibrate by oral gavage at low (25 mg/kg/day) and high (250
mg/kg/day) doses for 1, 3, and 7 days. Data shown are the mean ± SD for each group (n = 4). Asterisks (**)
indicate signiﬁcant (p < 0.01) changes from control. Signiﬁcance was assessed using Student t test.
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Figure 2. Examples of dose- and time-related gene expression changes using cDNA microarrays after
exposure to clofibrate. Rats received clofibrate by oral gavage at low (25 mg/kg/day) and high
(250 mg/kg/day) doses for 1, 3, and 7 days. Data shown are the mean from pooled samples (n = 4) run on
triplicate arrays. 
45
40
35
30
25
20
15
10
5
0
R
e
l
a
t
i
v
e
 
f
o
l
d
 
c
h
a
n
g
e
Day 1-low-GSK
Day 1-low-ULR
Day 3-low-ULR
Day 3-low-GSK
Day 7-low-GSK
Day 1-high-GSK
Day 1-high-ULR
Day 3-high-GSK
Day 3-high-ULR
Day 7-high-GSK
Day 7-low-ULR
Day 7-high-ULR
HCD
3KCTA + B ACOX ADH1 CYP4A1arrested at G2/M are those that are pro-
ceeding through the cell cycle. 
Upregulation of genes representing
increased β-oxidation of fatty acids (e.g.,
ACOX, 3KCTA+B) and metabolism of bile
acids were also seen at 3 days as well as
genes representative of peroxisome biogene-
sis. There was also downregulation of genes
associated with movement of bile acids and
xenobiotics into biliary canaliculi. At the
same time that fatty acid oxidation by the
liver was increasing, gluconeogenesis was
decreasing, as indicated by the down-
regulation of PEPCK. Examples of these
genes are shown in Tables 7–10 and in
Figures 2 and 3. 
Reproducibility across different in vivo
studies. The U.S. EPA analyzed gene
expression in individual RNA samples from
day 7 high- and low-dose animals treated at
Abbott. GSK (U.S.) and ULR analyzed
gene expression in pooled RNA from day-7
high- and low-dose animals treated at GSK
(U.K.). Gene expression data from individ-
ual animal samples indicated that 7 genes
were significantly (p < 0.05) upregulated
(maximum of 7.2-fold increase), and 12
were downregulated (maximum of 4.3-fold
decrease) in the high-dose group. The low-
dose group generated only one statistically
signiﬁcant gene expression change, namely,
heat shock protein 70 (HSP70). In compar-
ison, expression changes in the 7-day
pooled high-dose samples analyzed by GSK
(U.S.) ranged from a 43.3-fold increase to a
3.5-fold decrease. Changes in these same
samples analyzed by ULR ranged from a
4.9-fold increase to a 4.3-fold decrease.
Tables 8 and 9 show statistically signiﬁcant
gene expression changes in the individual
animal samples compared with those from
the pooled samples. 
Quantitative Real-Time Polymerase
Chain Reaction
Figure 3 shows the quantitative real-time
PCR results for the selected genes across dif-
ferent doses and time points using TaqMan
and SYBR green methods. These genes were
selected for conﬁrmatory studies on the basis
of their known modulation (up- and down-
regulation) by cloﬁbrate, both in this study
and in previous studies. In addition, they
were common to all microarray platforms
being used within the HWG and would
therefore allow cross-platform conﬁrmatory
studies to be performed. A comparison of
gene expression data from day 7 high-dose
samples obtained using quantitative real-
time PCR versus data generated using
cDNA microarrays is shown in Table 10.
The genes selected for conﬁrmatory analysis,
despite showing some quantitative differ-
ences in fold changes (particularly at the
high end of the upregulated genes), demon-
strated a qualitatively similar pattern of
expression between the quantitative real-
time PCR results and the microarray data.
PPARα, however, demonstrated equivocal
results. Although both methods of quantita-
tive real-time PCR on the pooled sample
showed the gene to be downregulated, the
GSK (U.S.) pooled sample microarray
analysis indicated upregulation; the ULR
pooled and U.S. EPA individual microarray
analyses showed no change.
Discussion 
Mechanism of Cloﬁbrate Action 
Clofibrate is a member of a large class of
diverse chemicals known as peroxisome
proliferators (PPs). Peroxisomes are subcel-
lular organelles that perform diverse meta-
bolic functions, including H2O2-derived
respiration, β-oxidation of very long chain
fatty acids, and cholesterol metabolism
(Mannaerts et al. 2000; Singh 1997). PPs are
thought to cause cancer by a nongenotoxic
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Table 7. Comparison of data (top upregulated genes) obtained for pooled RNA samples from high-dose
(250 mg/kg/day) 3-day cloﬁbrate-exposed rats.a
GenBank GSK (U.S.) ULR
Gene accession no.b (rank/fold change) (rank/fold change)
HCD K03249 1/465 ↑ 29.6 1/465 ↑ 5.9
CYP4A1 X07259 2/465 ↑ 26.4 8/465 ↑ 3.5
3KCTA+B M32801, J02749  3/465 ↑ 13.6 3/465 ↑ 4.8
Estradiol 17-β dehydrogenase 3  AF035156 4/465 ↑ 8.7 4/465 ↑ 4.7
ACOX J02752 6/465 ↑ 5.7 7/465 ↑ 3.9
CYP17 M21208 11/465 ↑ 4.3 5/465 ↑ 4.6
ADH1 M23995 12/465  ↑ 4.2 9/465 ↑ 2.6
Pololike serine threonine protein kinase  U10188 17/465 ↑ 3.1 10/465 ↑ 2.5
Abbreviations: CYP17, cytochrome P450 subfamily 17; ↑, increase.
aPooled RNA samples generated from one in vivo study (GSK, U.K.) were supplied to two laboratories, GSK (U.S.) and ULR,
for analysis on Atlas Rat Toxicology II cDNA arrays. Rank is based on ordering genes using fold change values. Data shown
are the mean from pooled samples (n = 4) run on triplicate arrays. bFrom GenBank (http://www.ncbi.nih.gov/GenBank/).
Table 9. Downregulated genes from high-dose (250 mg/kg/day) 7-day cloﬁbrate-treated rats. Comparison
of data from individual and pooled samples.a
Genbank U.S. EPAc GSK (U.S.)d ULRd
Gene accession no.b (fold change) (fold change) (fold change)
APO-A1 M00001 ↓ 4.3 ↓ 2.3 ↓ 4.3
PEPCK K03243 ↓ 2.5 ↓ 2.0 ↓ 2.8
CYP1A2 K02422 ↓ 2.3 ↓ 2.7 NC
Early growth response protein 1  M18416 ↓ 2.1 ↓ 3.5 NC
Activin, beta E AF089825 ↓ 2.0 ↓ 1.7 ↓ 1.5
G1/S-speciﬁc cyclin D1 D14014 ↓ 1.7 ↓ 1.9 ND
HSP70 Z27118 ↓ 1.7 ↓ 1.5 ↓ 1.1
CPT1 L07736 ↓ 1.7 ↑ 2.5 ↑ 4.2
Protein disulﬁde  M86870 ↓ 1.7 ↓ 1.6 ↓ 1.3
isomerase–related protein 
Tumor necrosis factor receptor 1 M63122 ↓ 1.6 ↓ 1.3 ↓ 1.2
Serine protease inhibitor  M32247 ↓ 1.5 NC ↓ 1.1
ABC transporter AJ003004 ↓ 1.4 ↑ 1.3 ND
Abbreviations: NC, no change; ND, not detected; ↑, increase; ↓, decrease.
aEleven genes demonstrated statistically signiﬁcant (p < 0.05) downregulation for samples obtained from individual animals
(n = 4) (U.S. EPA). These data are compared with gene expression data from pooled samples (n = 4) run on triplicate arrays.
Data shown are the mean of the replicates. bFrom GenBank (http://www.ncbi.nih.gov/GenBank/). cIndividual samples.
dPooled samples. 
Table 8. Upregulated genes from high-dose (250 mg/kg/day) 7-day cloﬁbrate-treated rats. Comparison of
data from individual and pooled samples.a
Genbank U.S. EPAc GSK (U.S.)d ULRd
Gene accession no.b (fold change) (fold change)] (fold change)
HCD K03249 ↑ 7.2 ↑ 43.3 ↑ 4.9
3KCTA+B M32801, J02749 ↑ 7.1 ↑ 16.4 ↑ 3.3
CYP4A1 X07259 ↑ 3.8 ↑ 20.3 ↑ 2.2
ACOX J02752 ↑ 3.1 ↑ 3.6 ↑ 1.4
CYP2B1 M11251 ↑ 1.6 NC ↓ 1.9
NAD(P)H dehydrogenase J020608 ↑ 1.4 ↓ 1.4 ND
40S ribosomal protein S30  X62671 ↑ 1.2 ↑ 1.4 NC
Abbreviations: NC, no change; ND, not detected; ↑, increase; ↓, decrease. 
aSeven genes demonstrated statistically signiﬁcant (p < 0.05) upregulation for samples obtained from individual animals
(n = 4) (U.S. EPA). These data are compared with gene expression data from pooled samples (n = 4), run on triplicate
arrays. Data shown are the mean of the replicates. bFrom GenBank (http://www.ncbi.nih.gov/GenBank/). cIndividual sam-
ples. dPooled samples. mechanism (Diez-Fernandez et al. 1998; Ito
et al. 1992), by indirectly altering gene
expression and affecting the phenotype of the
target cell. The response is most notable in
rodent liver, whereas humans are relatively
insensitive (Hertz and Bar-Tana 1998).
Many of the effects of cloﬁbrate and other
PPs are receptor mediated. Activation of
PPARα, a member of the nuclear superfamily
highly expressed in hepatocytes, cardiomyo-
cytes, enterocytes, and renal proximal tubule
cells, has been strongly correlated with peroxi-
some proliferation and liver cancer (Corton
et al. 2000). PPARs are ligand-activated tran-
scription factors that control gene expression
by interacting with specific DNA response
elements located upstream of responsive
genes. These elements, known as PP response
element motifs, are found in many genes,
including acyl-CoA, liver fatty acid binding
protein, microsomal CYP4A, a fatty acid
ω-hydroxylase, and growth regulatory genes
such as c-myc, c-Ha-ras, fos, jun, and egr-1
(Corton et al. 2000; Vanden Heuvel 1999).
The growth regulatory genes are pivotal in
the progression of the cell cycle, in particular
the transition from G1 to S phase. The oblig-
atory need for PPARα activation for the
expression of PP-induced events is evident
from observations that PPARα knockout
mice do not show the morphological and
biochemical changes typically observed in
rodents after acute or chronic administration
of PPs (Lee et al. 1995).
In Vivo Studies—Induction of
Cloﬁbrate-Induced Hepatotoxicity
To build a foundation on which to inter-
pret gene expression data, it is important to
understand how modulations in gene
expression correlate with clinical chemistry
and histopathological changes. The two
in vivo studies generally produced expected
outcomes with regard to changes in clinical
chemistry and histopathology. For exam-
ple, several dose- and time-related changes
associated with a disturbance of metabolic
function in the liver were observed after
clofibrate treatment. These included a
characteristic increase in liver weight (due
to hepatocyte hyperplasia and hyper-
trophy), midzonal mitoses, centrilobular
hypertrophy, and changes in clinical
pathology (e.g., lipid metabolism and clot-
ting parameters), as previously reported
(Kim et al. 1998; Popp et al. 1994). 
However, some biological responses dif-
fered between the two in vivo studies. For
example, at days 3 and 7, there was variance
in the percentage of liver weight increase,
which was also reﬂected in levels of ACOX
activity. ACOX is an enzyme speciﬁc to per-
oxisomes and is involved in the oxidation of
fatty acids (Kovacs et al. 2001; Lindauer
et al. 1994). Under conditions of induced
proliferation of the peroxisomes (e.g., admin-
istration of clofibrate), ACOX activity is
extensively increased (Latruffe et al. 2001).
Observed changes in clinical chemistry para-
meters also indicated differences in the bio-
logical response of the in vivo studies,
concordant with the differences in liver
weight increase. For example, a significant
reduction in total cholesterol levels was seen
in the GSK (U.K.) study at the high dose for
all time points. However, the Abbott study
demonstrated a signiﬁcant reduction at only
one dose/time point. Similarly, a reduction
in globulins and triglycerides was more pro-
nounced in the GSK (U.K.) study, as was
the increase in albumin concentrations. Such
differences in in vivo responses could be
caused by a number of factors, including the
source of the animals or differences in animal
husbandry (e.g., diet, cage type, bedding) at
the two in vivo exposure sites. In addition, as
pharmacokinetic analysis was not performed,
it is possible that difference in drug exposure
occurred between the two sites, despite the
fact that efforts were made to standardize the
treatment protocols between the two sites.
These in vivo differences could in turn
account for some of the differences in gene
expression noted between the two studies.
Corroboration of Gene Expression
Data—Comparison with 
Published Data
Corroboration of microarray data has
become an integral and very necessary
component of most studies using the tech-
nology. One way to verify microarray data is
to compare observed changes with those pre-
viously published for the same or similar
models. The gene changes induced in rat
liver after treatment with clofibrate have
been well documented. β-Oxidation of fatty
acids requires the presence of several enzymes
located in the peroxisomes and mitochondria
(Latruffe et al. 2001), and it has been shown
that PPs such as cloﬁbrate induce expression
of genes encoding ACOX, enoyl-CoA
hydratase, HCD (multifunctional enzyme),
and ketoacyl-CoA thiolase, all of which are
responsible for very long-chain fatty acid
β-oxidation in peroxisomes (Amacher et al.
1997; Hamadeh et al. 2002a; Schoonjans
et al. 1996). 
Evaluation of differential gene expression
data from the three laboratories performing
microarray analysis in this study revealed
gene expression patterns consistent with the
established literature for this class of com-
pound. For example, fatty ACOX and HCD
are the ﬁrst two enzymes of the peroxisomal
β-oxidation system. Reddy et al. (1986) pre-
viously demonstrated an upregulation of
these genes (9- to 15-fold) as early as 1 hr
after administration of cloﬁbrate. Although
there were some quantitative (fold change)
differences observed between the laboratories
in this study, upregulation of these genes was
seen as early as day 1 (Figure 2), with the
greatest upregulation being observed with
the high-dose group. In addition, HCD and
3-keto-acyl-CoA thiolase were consistently
upregulated at both days 3 and 7. This is in
accordance with earlier reports by Gerhold
et al. (2001).
Cloﬁbrate exposure in the current study
also induced CYP4A1 activity using both
microarrays and quantitative real-time
PCR (Table 10; Figures 2 and 3). The
transcriptional activation by clofibrate of
CYP4A1 through the PPARα receptor has
previously been reported in liver both
in vivo (Correia 1995; Simpson 1997) and
in vitro (Yaacob et al. 1997). 
In many studies, attention is focused
on genes induced as a result of chemical
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Table 10. Comparison of gene expression generated using quantitative real-time PCR and cDNA arrays from high-dose (250 mg/kg/day) 7-day cloﬁbrate-treated rats.a
Genbank  Microarray fold change Quantitative real-time PCR
Gene accession no.b U.S. EPA ULR GSK (U.S.) TaqMan SYBRgreen
HCD K03249 ↑ 7.2 ↑ 4.9 ↑ 43.3 ↑ 17.1 ↑ 18.8
CYP4A1 X07259 ↑ 3.8 ↑ 2.2 ↑ 20.3 ↑ 81.2 ↑ 15.7
ACOX J02752 ↑ 3.1 ↑ 1.4 ↑ 3.7 ↑ 9.7 ↑ 2.1
APO-A1 M00001 ↓ 4.3 ↓ 4.3 ↓ 2.3 Did not amplify  ↓ 3.2
CEH X65083 NC NC ↑ 8.3 ↑ 11.0 ↑ 21.7
PEPCK K03243 ↓ 2.5 ↓ 2.8 ↓ 2.0 ↓ 5.9 ↓ 1.9
PON1 U94856 NC NC ↓ 1.5 ↓ 2.4 ↓ 1.5
PPARα M88592 NC NC ↑ 1.8 ↓ 4.5 ↓ 1.2
Abbreviations: NC, no change; ND, not detected; ↑, increase; ↓, decrease.
aData from the U.S. EPA are the mean from individual animals (n = 4). Data from GSK and ULR are from pooled samples (n = 4) run on triplicate arrays. Data shown are the mean of repli-
cates. Quantitative real-time PCR data are shown for TaqMan and SYBR green methods.  bFrom GenBank (http://www.ncbi.nih.gov/GenBank/).treatment. However, it is equally important
to monitor those genes that have been
downregulated or switched off. In this
study, decreased lipid levels in serum are
suggested by the downregulation of APO-
A1, as demonstrated by all three laborato-
ries. These observations were conﬁrmed by
quantitative real-time PCR (Table 10;
Figure 3) and are consistent with the ﬁnd-
ings of Vu-Dac et al. (1998) and Staels
et al. (1992), who reported that the ﬁbrates,
including clofibrate, provoke a dose-
dependent decrease in liver APO-A1 mRNA
levels that was associated with a lower
transcription rate of the APO-A1 gene. 
Exposure of male rats to clofibrate for
3 days also results in a downregulation of
PEPCK using microarrays (Gerhold et al.
2001). This indicates decreased lipid
turnover as well as decreased gluconeogenesis
mediated by PEPCK in the liver. Results
from this study are consistent with these
findings. Downregulation of PEPCK was
noted in the high-dose group after 1, 3, and
7 days of exposure using microarrays and
quantitative real-time PCR. 
Corroboration of Gene Expression
Data—Quantitative Real-Time PCR
To confirm some of key clofibrate gene
changes identiﬁed using cDNA arrays, nine
genes were selected for quantitative real-
time PCR analysis using TaqMan and
SYBR green. Using these two methods, the
selected genes demonstrated dose- and
time-dependent patterns of change (Figure
3). The quantitative differences observed
were most likely due to the different primer
sequences and PCR reaction efﬁciencies of
the two methods. 
A comparison of gene expression data
obtained using quantitative real-time PCR
and cDNA arrays (Table 10) shows that,
despite quantitative differences in fold
changes (particularly at the high end of the
upregulated genes), a qualitatively similar
pattern of gene expression between the
quantitative real-time PCR results and the
microarray data was seen. Quantitative dif-
ferences between cDNA array measurements
and quantitative real-time PCR values are
not surprising, as microarrays are, at best,
semiquantitative and suffer from compres-
sion of values at high fold-changes. Gerhold
et al. (2001) also reported similar quantita-
tive differences between quantitative real-
time PCR and microarray data from rats
exposed to cloﬁbrate. For example, CYP4A1
demonstrated a 9-fold upregulation using
microarrays but a 47-fold upregulation
using quantitative real-time PCR, a ﬁnding
similar to those from this study. In addition,
quantitative real-time PCR is able to detect
relatively small gene expression changes
deemed undetectable using microarrays
(Table 10). It is therefore suggested that
microarrays are a valuable way to screen
many hundreds or thousands of genes that
may respond to a chemical stimulus and
that quantitative real-time PCR can be used
to conﬁrm observations on selected genes of
particular interest. 
Comparison of Microarray Data
across Laboratories
Tables 8 and 9 are lists of genes that were
signiﬁcantly up- and downregulated in the
analysis of day 7 high- and low-dose individ-
ual animals, respectively. Although analysis
of the pooled samples reported simple fold
changes rather than statistically significant
changes, the results from the three laborato-
ries demonstrate a considerable degree of
similarity, particularly among the genes
where the expression changes were quite
large. As the changes became smaller, dis-
crepancies occur, usually in the form of one
laboratory showing an opposite directional
change to the other two or indicating no
change. There was no clear pattern, however,
with all three laboratories being the source of
discordant data on at least one occasion.
Sources of Variation—Technical
Several explanations exist for the generation
of discordant data. Consequently, an
important aspect of this study was the eval-
uation of the robustness of the gene expres-
sion changes from different laboratories
performing microarray analysis. Therefore,
each laboratory involved in the study per-
formed the microarray experimental and
data analysis phases using the procedures
and protocols routinely used in that labora-
tory. Table 3 is a list of several technical dif-
ferences between the protocols used in each
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Figure 3. qRT-PCR analysis of gene expression changes using (A) TaqMan and (B) SYBR green methods.
Rats received cloﬁbrate by oral gavage at low (25 mg/kg/day) and high (250 mg/kg/day) doses for 1, 3, and
7 days. Data shown are the mean of duplicates. Note: APO-A1 failed to amplify using TaqMan.laboratory that could have had an impact
on the data generated. They include a)t h e
condition of cDNA membranes (i.e., use of
stripped and reprobed microarrays com-
pared with new microarrays); b) the choice
of radioisotope for probe labeling (i.e., 32P
or 33P); c) the probe hybridization tempera-
ture (i.e., 62°C vs. 68°C); and d) the image
capture system (i.e., phosphorimager com-
pared with X-ray ﬁlm). 
Reproducibility of microarray results
across different laboratories. Two of the
laboratories [GSK (U.S.) and ULR] ana-
lyzed pooled RNA samples from a single
in vivo study, thus reducing the impact of
biological variability but allowing differ-
ences due to technical/experimental varia-
tions to be highlighted. A comparison of
the gene expression data obtained by the
two laboratories from a single source of
pooled RNA samples indicated that, despite
some quantitative differences [most likely
due to differences in membrane use and
image capture/analysis methods used in the
two laboratories (Table 3)], there was gen-
erally good concordance between the gene
expression data. For example, of the top 20
upregulated genes ranked by fold change
values identiﬁed by each laboratory, 8 were
common to both laboratories (Table 7). 
However, examples of discordant data
were also found. For example, microarray
data from two of the three laboratories per-
forming microarray analysis [U.S. EPA and
GSK (U.S.)] indicated a downregulation of
cyclin D1 (1.7-fold and 1.9-fold, respec-
tively) and CYP1A2 (2.3-fold and 2.7-fold,
respectively) for the 7-day high-dose sam-
ples, whereas no change was noted by
ULR. The U.S. EPA and GSK (U.S.) used
fresh membranes for each hybridization
andphosphorimaging plates as opposed to
the stripped and reprobed membranes and
X-ray film used by ULR. Such technical
variation may account for differences in the
ability to detect small changes in gene
expression, as seen in the ULR results.
Image analysis can also be a source of varia-
tion in ﬁnal data output. Where changes in
gene expression are small such as the cases
listed above, they can be significantly
affected by local background (which can be
variable across membranes) and bleedover
from adjacent genes if the latter are highly
expressed. Different methods of data analy-
sis were also used by the three laboratories,
and this may have also contributed to the
observed differences. 
Sources of Variation—Biological 
Reproducibility across different in vivo
studies. Differences in gene expression data
can also be biological in origin. The pool-
ing of samples for microarray analysis has
been used in the past to defray the cost of
microarray experiments, reduce the effect
of biological variation, and in some cases
overcome availability of limiting amounts
of tissue (e.g., from embryonic organs).
Unfortunately, this approach essentially
produces a sample size (n) of one animal.
Repeated microarray experiments with
such pooled RNA produces technical repli-
cates as opposed to true biological repli-
cates and thus does not allow calculation of
biologically significant changes in gene
expression between different dose groups
or time points. 
Another possible consequence of pool-
ing is to mask individual gene changes and
leave open the possibility of introducing
error due to individual outlier responses.
For example, liver mitochondrial carnitine
O-palmitoyltransferase I (CPT1) catalyses
the transfer of long-chain fatty acids
(LCFAs) for translocation across the mito-
chondrial membrane. Expression of the
CPT1 gene is induced by LCFAs as well as
by lipid-lowering compounds such as cloﬁ-
brate (Louet et al. 2001). In this study,
both laboratories examining pooled RNA
samples observed an approximate 3-fold
induction of CPT1 after 7-day treatment
with the high dose of clofibrate. The U.S.
EPA, however, when analyzing individual
animals, observed a signiﬁcant downregula-
tion of this gene at the same time point.
One possible biological explanation for this
could be that the source of the RNA sam-
ples used by the U.S. EPA (i.e., Abbott
Laboratories) was different from that pro-
viding the pooled RNA used by GSK (U.S.)
and ULR [i.e., GSK (U.K.)]. As previously
discussed, differences were noted in the
in vivo response, and these could explain
the observed differences. However, this type
of contradictory result (also seen with
CYP2B1) may also reﬂect the phenomenon
of data skewing by individual responses.
This most often occurs in pooled samples of
a low n, where an extreme response in one
outlier animal skews or nullifies changes
seen in the majority. Indeed, the chances of
this effect occurring are increased with the
use of an outbred strain such as Sprague-
Dawley. Furthermore, previous reports have
suggested that some genes are hypervariable
among individual animals (Gerhold et al.
2001). Such differences are most likely
caused by polymorphisms in the gene regu-
latory regions, and therefore consideration
should be given to the region of the gene
selected for the probe, as probes targeted
toward a polymorphic locus would demon-
strate increased interindividual variability.
In this study for example, one animal of the
pooled samples may have responded to
cloﬁbrate with a large increase in expression
of CPT1, whereas the others showed a
small downregulation of this gene. 
Individual Analysis
Running samples from multiple individual
animals is more costly than using pooled
samples. However, it is advantageous in
that it can be used to identify outliers and
also permits the calculation of statistically
significant changes in gene expression.
Nevertheless, a balance must still be struck
between the number of individual animals
that can be examined and the statistical
rigor required. In this study, the n for each
group of individual analyses was four. This
is a relatively low number for computation
of statistically signiﬁcant changes in differ-
ent exposure groups. A common conse-
quence of using a low n is that variance in
the level of gene expression is high, which
in turn reduces the number of significant
gene changes. Thus, in the analysis of indi-
vidual samples in this study, only 20 genes
were deemed significantly changed. Genes
that might have been expected to be signiﬁ-
cantly changed but were not included
PPARα, enoyl-CoA hydratase, and CEH. It
is this kind of discrepancy that has led
many researchers to believe that observing
change or lack of change in expression of
single genes has little value. Instead, identi-
fication of the gene expression pathways
being affected appears to be a more robust
method of identifying exposure to and
effects of drugs and toxicants. In this case
for example, it is still clear from the signiﬁ-
cant gene changes that β-oxidation of fatty
acids is increased, as would be expected
after exposure to a PP.
In future studies careful consideration
must be given to the feasibility of using RNA
samples from individual animals as opposed
to pooled samples. Although recent evidence
suggests that selection of certain pooling
schemes can provide adequate statistical
power and improve efﬁciency and cost effec-
tiveness (Peng et al. 2003), the weight of evi-
dence still supports the use of individual
animals where possible. Such experiments,
although more time and resource intensive
than the use of pooled samples, permit
analysis of interindividual (biological) varia-
tion. This is an important consideration in
gene expression studies, as biological varia-
tion on the whole normally exceeds experi-
mental variation. Individual gene expression
data can also be useful in trying to under-
stand why an individual animal might have
shown an outlier clinical response to the test
chemical. Individual variation, which exists
even in inbred strains, lies at the very heart of
pharmacogenomics and is usually attribut-
able, at least in part, to polymorphisms in
key drug-metabolizing genes that alter either
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Summary 
The results of this study demonstrate
clofibrate-induced hepatotoxicity in a
rodent model identified by conventional
histopathology and clinical chemistry para-
meters, gene expression analysis using
cDNA microarrays, and conﬁrmatory stud-
ies using quantitative real-time PCR. The
results indicate that despite some variability
in the quantitative nature of the data,
robust gene changes relating to the mecha-
nism of clofibrate-induced hepatotoxicity
were identiﬁed across laboratories perform-
ing the microarray analysis using pooled
and individual samples from two different
in vivo studies on the same cDNA array
platform. This study demonstrates the
potential for gene expression profiling to
identify toxic hazards by the identification
of mechanistically relevant markers of toxic-
ity. In conclusion, toxicogenomics has the
potential to provide new and refined
approaches to hazard identification and
safety evaluation based on the identiﬁcation
of biologically relevant markers of toxicity.
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